Rao Vikram, Munasinghe Anna
Department of General Medicine, Monash Medical Centre, Clayton, Melbourne, Victoria, Australia
Department of Nephrology, Monash Medical Centre, Clayton, Melbourne, Victoria, Australia.
BMJ Case Rep. 2021 Apr 28;14(4):e240719. doi: 10.1136/bcr-2020-240719.
Rivaroxaban is a commonly used anticoagulant agent for treatment and prevention of thromboembolism. There are case reports demonstrating an association between its use and drug-induced liver injury. However, this has not been reported in a patient who previously tolerated apixaban. An 88-year-old man presented to hospital with worsening lethargy, jaundice and vomiting. He had severely elevated liver transaminases, an abnormal coagulation profile and elevated bilirubin in keeping with acute liver injury. This is in the context of having had his anticoagulation medication switched from apixaban to rivaroxaban 2 weeks prior. The patient recovered well after cessation of rivaroxaban, suggesting that it was the likely offending agent. The mechanism of rivaroxaban-induced liver injury remains to be investigated. Drug-induced liver injury should be discussed and monitored for as a potential adverse reaction when commencing rivaroxaban, even if a patient has previously tolerated a drug of the same class.
利伐沙班是一种常用于治疗和预防血栓栓塞的抗凝剂。有病例报告表明其使用与药物性肝损伤之间存在关联。然而,此前耐受阿哌沙班的患者中尚未有此报告。一名88岁男性因嗜睡、黄疸和呕吐加重入院。他的肝转氨酶严重升高、凝血指标异常且胆红素升高,符合急性肝损伤表现。这发生在其抗凝药物于两周前从阿哌沙班换为利伐沙班之后。停用利伐沙班后患者恢复良好,提示它可能是致病因素。利伐沙班所致肝损伤的机制仍有待研究。开始使用利伐沙班时,即使患者此前耐受同一类药物,也应讨论并监测药物性肝损伤这一潜在不良反应。